Herceptin gives disappointing results in lung cancer trial

January 12, 2004

Trastuzumab (Herceptin) - a treatment that has increased survival in many breast cancer patients - has failed to live up to hopes that it might also help lung cancer patients.

In a Phase II trial of over 100 patients with non-small-cell lung cancer (NSCLC) reported (Tuesday 13 January) in Annals of Oncology[1], those treated with trastuzumab in combination with two chemotherapy agents gemcitabine and cisplatin, did no better than patients treated with gemcitabine and cisplatin alone.

There was a hint in the results that there could be a very small subgroup of lung cancer patients who may benefit. These are patients with extremely strong over-expression or amplification of HER2 - the gene that trastuzumab targets[2]. The international research team[3] believes that any future trials should focus on patients with high levels of HER2 over-expression or gene amplification. However, studies on those with the strongest possible over-expression or amplification will be difficult to carry out because the numbers of eligible patients will be small.

Lead researcher, Dr Ulrich Gatzemeier, Head of the Department of Thoracic Oncology, Zentrum für Pneumologie und Thoraxchirurgie, Krankenhaus Grosshansdorf, Germany, said that trastuzumab, combined with chemotherapy, had already shown major clinical benefit in women with HER2 positive breast cancer, including a significant increase in survival. As cell-line studies on HER2 positive NSCLC had shown that trastuzumab had an even greater synergy with gemcitabine and cisplatin than it had in breast cancer cells there was a rationale for believing that it might also benefit lung cancer patients.

"It was disappointing therefore to find that the survival times and the time to the disease progressing were very similar - between six and seven months for both the trastuzumab and control arms. However, we did find that the trastuzumab/chemotherapy combination was well tolerated and that five out of the six patients with extremely high levels of HER2 responded better than other HER2 patients. It was nearly eight and half months before their disease progressed compared with just over six months for the patients with less high HER2 levels. Unfortunately, this extremely high HER2 group made up less than two per cent of all the 619 patients we originally screened for trial eligibility and our data suggest that although nearly 60 per cent of NSCLC patients overall are HER2 positive any possible benefit of trastuzumab is likely to be confined to under five per cent of all patients with advanced NSCLC. That's only about 1,200 people per year in Germany. This makes future recruitment to clinical trials problematic and means that the likely clinical use of trastuzumab for NSCLC will be limited."

Dr Gatzemeier said that ongoing trials with other chemotherapy combinations might further define trastuzumab's potential use in NSCLC. But, it was important that any new trials focused on patients with high HER2 over-expression or amplification.

The main reason for the failure, according to Dr Gatzemeier, was that the majority of patients had lower levels (1+ and 2+) of high HER2 over-expression. Trastuzumab added nothing to an effective chemotherapy like cisplatin/gemcitabine - in accordance with other trials (INTACT, TALENT AND TRIBUTE) in which the aim was to inhibit receptors of epidermal growth factors. It was also possible that blocking only one of the growth factors was ineffective in NSCLC while there were parallel signalling pathways allowing the cancer to progress.
-end-
[1] Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Annals of Oncology 15: 19-27.

[2] Trastuzumab (Herceptin) is a humanized monoclonal antibody rationally developed to target HER2 over-expressing cells. It has an additive or synergistic activity in combination with various cytotoxic chemotherapy in pre-clinical studies of breast cancer and NSCLC and is an effective new treatment in HER2 positive breast cancer.

[3] The trial involved an international team of researchers from Germany, Canada, the Netherlands, Italy and the UK, plus Roche Products Ltd., manufacturers of Herceptin.

Notes:

1 Annals of Oncology is the monthly journal of the European Society for Medical Oncology.

Please acknowledge the journal as the source in any reports.

2 Annals of Oncology website: http://www.annonc.oupjournals.org
PDF of article available from Margaret Willson or from web site: http://annonc.oupjournals.org/cgi/content/full/15/1/19

European Society for Medical Oncology

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.